Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.

Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.

Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.

Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.

Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.

He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.

Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.613
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67698
+1 418-691-3154
Louis.Lacombe@crchudequeb...

Latest news

180 entries « ‹ 1 of 18 › »

Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

Journal Article

Lancet Oncol, 24 (8), 2023.

Abstract | Links:

Molina OE, LaRue H, Simonyan D, Hovington H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A, Fradet Y

High infiltration of CD209+ dendritic cells and CD163+ macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Diop MK, Molina OE, Birlea M, LaRue H, Hovington H, Têtu B, Lacombe L, Bergeron A, Fradet Y, Trudel D

Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study

Journal Article

Cancers (Basel), 15 (8), 2023.

Abstract | Links:

Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert JP, Pouliot F, Pelletier M, Audet-Walsh É

Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer

Journal Article

Mol Oncol, 2023.

Abstract | Links:

Moussa H, Robitaille K, Pelletier JF, Tourigny R, Fradet Y, Lacombe L, Toren P, Lodde M, Tiguert R, Dujardin T, Caumartin Y, Duchesne T, Julien P, Savard J, Diorio C, Fradet V

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)

Journal Article

Nutrients, 15 (6), 2023.

Abstract | Links:

Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C

Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer

Journal Article

J Urol, 209 (2), 2023.

Abstract | Links:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Journal Article

Cancer Lett, 553 , 2023.

Abstract | Links:

Rouleau M, Nguyen Van Long F, Turcotte V, Caron P, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C

Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer

Journal Article

Br J Cancer, 128 (2), 2023.

Abstract | Links:

Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P

Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer

Journal Article

Urol Oncol, 40 (12), 2022.

Abstract | Links:

Rouleau M, Neveu B, Caron P, Morin F, Toren P, Lacombe L, Turcotte V, Lévesque É, Guillemette C, Pouliot F

Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level

Journal Article

J Urol, 208 (6), 2022.

Abstract | Links:

180 entries « ‹ 1 of 18 › »
Signaler des ajouts ou des modifications

Active projects

  • Soutien à la recherche, from 2017-07-01 to 2024-06-30
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31

Recently finished projects

  • Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression, from 2019-04-01 to 2022-03-30
Data provided by the Université Laval research projects registery